Panacea Biotec stock gains 3% after company wins ₹20.79 Cr Td vaccine contract from CMSSPanacea Biotec stock gains 3% after company wins ₹20.79 Cr Td vaccine contract from CMSS

Introduction

Leading vaccine manufacturer has secured a ₹20.79 crore order from a government agency to supply Diphtheria and Tetanus vaccines between 2026 and 2028.

Also Read: BSE Ltd gets SEBI approval to launch derivatives on Focused IT Index, stock in focus

Share price movement of Panacea Biotec

On April 13, 2026, Panacea Biotec Ltd opened at ₹320.90, down 1.56% from its previous close of ₹326.00. The stock reached a high of ₹336.00 (3.07%) and a low of ₹314.35. By 11:04 AM, it traded at ₹334.35, a 2.56% increase, with a market cap of ₹2,047.92 crore.

Panacea Biotec Wins Vaccine Order

Panacea Biotec Limited has received a Letter of Award from Central Medical Services Society under the Ministry of Health and Family Welfare, Government of India, dated April 10, 2026.

The company will supply Diphtheria and Tetanus Vaccine for adults and adolescents in multiple tranches. Supplies will begin around September or October 2026 and continue until November or December 2028.

The total contract value stands at ₹20.79 crore. The order is awarded by a domestic entity and involves supply of Td vaccines to Central Medical Services Society.

Stock performance of Panacea Biotec for period of 1 week, 6 months, and 1 year

Panacea Biotec Ltd delivered a 1-week return of 1.57%, a 6-month return of -27.6%, and a 1-year return of -27.6%.

Also Read: JSW Energy completes full acquisition move with remaining 26% stake buy in JMPCL

Shareholding pattern of Panacea Biotec

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	72.50%	72.50%	72.50%
FII	1.40%	1.10%	0.80%
DII	1.90%	1.80%	1.50%
Public	24.30%	24.70%	25.20%

About Panacea Biotec

Panacea Biotec Ltd (NSE: PANACEABIO) is a research-based biotechnology company engaged in vaccines, pharmaceuticals, nutraceuticals, and global supply of WHO pre-qualified polio vaccines.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs